Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74…
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today…
CDC reports burden of six hard-to-treat superbugs increased by a combined 20% in 2021 and 2022 compared with 2019CDC call…
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded…
CHICAGO, July 29, 2024 /PRNewswire/ -- The global healthcare RTLS market size is expected to grow from USD 2.3 billion in…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Journal of Orthopaedics in…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Journal of Orthopaedics in…
Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis…
Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite ExpansionNASHUA, N.H. and WILLIAMSVILLE, N.Y. and RALEIGH, N.C.,…
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage…